SSSI for diltiazem

Manufacturing issues have led to a major supplier discontinuing two brands of the hypertension medicine The Therapeutic Goods Administration (TGA) says Sanofi-Aventis Australia will discontinue two brands of diltiazem 360 mg controlled-release capsules, but substitutions are available. The pharmaceutical company made the call due to manufacturing issues, the TGA said. The affected medicines are: Cardizem